The forecast for antibacterial medicine sales per capita in Canada indicates a continuous decline from 2024 to 2028, dropping from 8.9 to 6.7 USD PPP per capita. Comparing each year, there is an average annual decrease of approximately 6%. The compound annual growth rate (CAGR) over this period highlights a consistent downward trend, drawing from the actual values observed in 2023 and earlier.

Future trends to watch for include:

The impact of increased antibiotic resistance and its influence on consumption patterns.
Advancements in alternative treatments that may replace traditional antibacterial medications.
Government policies on antibiotic stewardship programs aimed at reducing usage.